A cell therapy led to tumor responses in 95% of 37 lymphoma patients
Lyell Immunopharma (LYEL) reported positive clinical data for ronde-cel, a CAR T-cell therapy, in lymphoma patients. In two trials, ronde-cel showed 91-95% overall response rates and 76-77% complete response rates. The data will be presented at the ASH 2026 meeting. Ronde-cel has received FDA designations for relapsed/refractory LBCL. Lyell expects full pivotal data in mid-2027 and plans a BLA submission in the second half of 2027.
How this was made
The 30-second read
Why it matters
The disclosed response rates are among the highest reported for LBCL CAR‑T candidates, potentially accelerating FDA review and market adoption.
Market read
First public release of high‑response data for LYEL's lead product, likely to influence stock price and sector sentiment ahead of the ASH conference.
What to watch
Potential competition from other dual‑target CAR‑T candidates and the need for longer‑term safety data.
Background
Lyell Immunopharma (NASDAQ: LYEL) is a late‑stage biotech focused on next‑generation CAR‑T therapies for hematologic malignancies.
Ticker impact
Lyell Immunopharma disclosed updated Phase 1/2 and pivotal trial data showing 95% overall response rate in 2L LBCL patients, a first public disclosure of these results.
likely upward pressure as the market prices in the high response rates and potential regulatory approval path.
First-time release of pivotal efficacy data for a late‑stage CAR‑T candidate; such data historically trigger price moves in biotech stocks.
Market effects
Strengthens the broader CAR‑T and cell‑therapy sector, potentially lifting peers with similar pipelines.
U.S. biotech market may see modest gains; limited immediate impact outside the sector.
Limited to biotech investors; no broad macro effect.
Counterpoint
Skeptics may argue that early‑stage data can be misleading and that regulatory hurdles remain, suggesting caution.
Key entities
- CompanyLyell Immunopharma, Inc.
Developer of the ronde‑cel CAR‑T therapy.
- ConferenceAmerican Society of Hematology (ASH)
Venue where the data will be presented.
